Otsuka adds new Phase 3 Voyxact data in IgA nephropathy

CURRENT BRIEF VERSION: Otsuka said new Phase 3 VISIONARY analyses for Voyxact, its APRIL inhibitor sibeprenlimab-szsi, showed continued benefit in adults with IgA nephropathy at risk for progression, including faster and higher rates of microscopic hematuria resolution alongside previously reported proteinuria reductions. The company presented the data at the 2026 ISN World Congress of Nephrology, building on Voyxact’s FDA accelerated approval in November 2025 to reduce proteinuria in adults with primary IgA nephropathy. That approval was based on interim VISIONARY data, and full confirmation still depends on whether the ongoing study shows a benefit on kidney function decline, measured by eGFR at 24 months. Otsuka is also broadening its broader pipeline elsewhere: separately, the company has agreed through Otsuka America to acquire Transcend Therapeutics for about $1.225 billion, including $700 million upfront and up to roughly $525 million in sales milestones, adding late-stage PTSD candidate TSND-201 to its portfolio. (otsuka-us.com)

Why it matters: For veterinary professionals tracking translational renal medicine, the Voyxact story is another sign that kidney drug development is moving upstream, from symptom control toward disease-specific immune targets. FDA reviewers described IgA nephropathy as a serious disease with substantial unmet need, and KDIGO’s 2025 guideline update reflects how quickly the treatment landscape is changing. The practical question now isn’t whether APRIL inhibition lowers proteinuria, but whether that biologic effect will translate into durable preservation of kidney function, which is the endpoint that will matter most for long-term positioning, guidelines, and payer confidence. Otsuka’s willingness to spend heavily on other late-stage assets, including Transcend’s TSND-201 with Phase 3 PTSD recruitment underway, also signals a company still deploying capital aggressively across specialty and CNS development. (accessdata.fda.gov)

What to watch: The next key catalyst is the 24-month eGFR readout from VISIONARY, which Otsuka previously said was expected in early 2026 and is intended to support traditional FDA approval. Separately, the Transcend deal is expected to close in Q2 2026. (otsuka.co.jp)